Published On: Wed, Nov 25th, 2015

Teva Pharmaceuticals licenses migraine treatment candidates

Teva to Receive Worldwide Development and Commercial Rights to Novel CGRP Antagonists; Heptares to Receive $10 Million Upfront with up to $400 Million in Potential Milestone Payments.

Teva CEO Erez Vigodman

 

Teva Pharmaceutical Industries Ltd. and UK-based Heptares Therapeutics, a subsidiary of Tokyo-based Sosei Group have announced a licensing of its migraine treatment candidates.

Under the agreement Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.

Heptares will receive an advance payment of $10 million, and is eligible to receive milestone payments of up to $400 million, on top of which it will be in line for royalties on net sales of products resulting from the collaboration.

“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody, ” said Dr Michael Hayden, president of Global Research & Development and the chief scientific officer at Teva.

Malcolm Weir, chief executive officer of Heptares, said: “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”

Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems